← Human Trials & Peer-Reviewed Studies
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
Plain-language guide to PMID 33762428 (2021): double-blind randomized controlled trial study of Glatiramer Acetate, multiple sclerosis.
Key Facts
- PMID
- 33762428
- Journal
- Neurology(R) neuroimmunology & neuroinflammation
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Bellmann-Strobl J et al. (21 authors)
- DOI
- 10.1212/NXI.0000000000000981
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glatiramer Acetate in the context of multiple sclerosis in this randomized controlled trial publication.
Clinical trial registration number: NCT00525668.
Who Took Part
PubMed indexes the participants as young adults, adults and middle-aged adults.
The researchers enrolled patients with RRMS (aged 18-60 years, Expanded Disability Status Scale [EDSS] score 0-6.5), receiving stable GA treatment in a multicenter, prospective, double-blind, phase II, randomized controlled trial.
The primary outcome was the proportion of patients without new hyperintense lesions on T2-weighted (T2w) brain MRI within 18 months.
How the Study Was Run
In design terms this was a randomized, double-blind and multicenter study.
Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Glatiramer Acetate.
Running at several centres spread the Glatiramer Acetate study over different clinics and patient groups.
The timeline in the abstract includes 18 months.
Secondary end points included additional MRI and clinical parameters.
Immunologic effects of EGCG were investigated in exploratory experiments.
What Was Measured
The subject headings attached to it are Brain, Catechin, Glatiramer Acetate, Magnetic Resonance Imaging and Multiple Sclerosis, Relapsing-Remitting.
What This Means in Plain Language
The paper is a randomized, double-blind and multicenter study of Glatiramer Acetate in people with multiple sclerosis over 18 months.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (Neurology(R) neuroimmunology & neuroinflammation), a journal based in United States.
More context: the Glatiramer Acetate compound page, Multiple sclerosis research.
Our Notes on the Compound
Glatiramer Acetate: A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.